FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135260101> ?p ?o ?g. }

• W3135260101 endingPage "308" @default.
• W3135260101 startingPage "295" @default.
• W3135260101 abstract "Dysregulation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin signaling is common in both indolent and aggressive forms of malignant lymphoma, for which several targeted therapies have been developed. Copanlisib is a highly selective and potent intravenous pan-class I PI3K inhibitor that has demonstrated durable objective responses and a manageable safety profile in heavily pre-treated patients with indolent lymphomas. As a result, copanlisib monotherapy received accelerated approval from the US Food and Drug Administration for the treatment of adults with relapsed follicular lymphoma who have received at least two systemic therapies, and breakthrough designation for patients with pre-treated relapsed or refractory marginal zone lymphoma. Hyperglycemia and hypertension are among the most frequently reported adverse events with copanlisib monotherapy, and are infusion-related, transient, and manageable with standard therapies. Mild diarrhea is also a common adverse event with copanlisib monotherapy; there is no evidence of worsening severity of diarrhea, or serious gastrointestinal toxicities such as colitis or severe liver enzyme elevations, which have been reported with orally administered PI3K inhibitors. The intravenous route of administration and intermittent dosing schedule of copanlisib may support a favorable tolerability profile over continually administered oral alternatives. Ongoing studies of copanlisib in combination with rituximab and standard-of-care chemotherapy in patients with relapsed indolent lymphoma have the potential to support the use of copanlisib in the second-line setting, providing a much-needed additional therapeutic option in this underserved patient population." @default.
• W3135260101 created "2021-03-15" @default.
• W3135260101 creator A5012590429 @default.
• W3135260101 creator A5037878906 @default.
• W3135260101 creator A5090442154 @default.
• W3135260101 date "2021-03-09" @default.
• W3135260101 modified "2023-09-27" @default.
• W3135260101 title "Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives" @default.
• W3135260101 cites W19457734 @default.
• W3135260101 cites W1971379086 @default.
• W3135260101 cites W1981711832 @default.
• W3135260101 cites W1989007214 @default.
• W3135260101 cites W1997640760 @default.
• W3135260101 cites W2008815830 @default.
• W3135260101 cites W2009886463 @default.
• W3135260101 cites W2019407178 @default.
• W3135260101 cites W2030840011 @default.
• W3135260101 cites W2037796411 @default.
• W3135260101 cites W2042258092 @default.
• W3135260101 cites W2044685551 @default.
• W3135260101 cites W2070487917 @default.
• W3135260101 cites W2071541545 @default.
• W3135260101 cites W2083263906 @default.
• W3135260101 cites W2087861588 @default.
• W3135260101 cites W2100178666 @default.
• W3135260101 cites W2106715939 @default.
• W3135260101 cites W2113956910 @default.
• W3135260101 cites W2124593509 @default.
• W3135260101 cites W2128855114 @default.
• W3135260101 cites W2145550199 @default.
• W3135260101 cites W2149098481 @default.
• W3135260101 cites W2151963356 @default.
• W3135260101 cites W2160093471 @default.
• W3135260101 cites W2165404212 @default.
• W3135260101 cites W2169450835 @default.
• W3135260101 cites W2198189188 @default.
• W3135260101 cites W2343358448 @default.
• W3135260101 cites W2345838610 @default.
• W3135260101 cites W2418229423 @default.
• W3135260101 cites W2464635942 @default.
• W3135260101 cites W2474592988 @default.
• W3135260101 cites W2525724642 @default.
• W3135260101 cites W2571275916 @default.
• W3135260101 cites W2588813801 @default.
• W3135260101 cites W2599644610 @default.
• W3135260101 cites W2729141564 @default.
• W3135260101 cites W2735226272 @default.
• W3135260101 cites W2761177724 @default.
• W3135260101 cites W2762226752 @default.
• W3135260101 cites W2773804840 @default.
• W3135260101 cites W2803079541 @default.
• W3135260101 cites W2883482938 @default.
• W3135260101 cites W2886323375 @default.
• W3135260101 cites W2886504687 @default.
• W3135260101 cites W2901542804 @default.
• W3135260101 cites W2912319186 @default.
• W3135260101 cites W2940228483 @default.
• W3135260101 cites W2940388007 @default.
• W3135260101 cites W2948442338 @default.
• W3135260101 cites W2952605700 @default.
• W3135260101 cites W2952842269 @default.
• W3135260101 cites W2955513779 @default.
• W3135260101 cites W2971444300 @default.
• W3135260101 cites W2986196170 @default.
• W3135260101 cites W2997593504 @default.
• W3135260101 cites W3000359231 @default.
• W3135260101 cites W3005797416 @default.
• W3135260101 cites W3024407124 @default.
• W3135260101 cites W3031657380 @default.
• W3135260101 cites W3032487095 @default.
• W3135260101 cites W3042886835 @default.
• W3135260101 cites W3097629244 @default.
• W3135260101 cites W4210490242 @default.
• W3135260101 doi "https://doi.org/10.1007/s11523-021-00802-9" @default.
• W3135260101 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7941125" @default.
• W3135260101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33687623" @default.
• W3135260101 hasPublicationYear "2021" @default.
• W3135260101 type Work @default.
• W3135260101 sameAs 3135260101 @default.
• W3135260101 citedByCount "13" @default.
• W3135260101 countsByYear W31352601012021 @default.
• W3135260101 countsByYear W31352601012022 @default.
• W3135260101 countsByYear W31352601012023 @default.
• W3135260101 crossrefType "journal-article" @default.
• W3135260101 hasAuthorship W3135260101A5012590429 @default.
• W3135260101 hasAuthorship W3135260101A5037878906 @default.
• W3135260101 hasAuthorship W3135260101A5090442154 @default.
• W3135260101 hasBestOaLocation W31352601011 @default.
• W3135260101 hasConcept C126322002 @default.
• W3135260101 hasConcept C143998085 @default.
• W3135260101 hasConcept C197934379 @default.
• W3135260101 hasConcept C2778375690 @default.
• W3135260101 hasConcept C2779338263 @default.
• W3135260101 hasConcept C2908647359 @default.
• W3135260101 hasConcept C71924100 @default.
• W3135260101 hasConcept C90924648 @default.
• W3135260101 hasConcept C99454951 @default.
• W3135260101 hasConceptScore W3135260101C126322002 @default.

• next